Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
Open accessThe DOI matches its Crossref record; 113 of the 117 references it cites were found in a registry or an index.
Abstract
Aberrant activation of Wnt/β-catenin signaling plays a central role in the pathogenesis of a wide variety of malignancies and is typically caused by mutations in core Wnt pathway components driving constitutive, ligand-independent signaling. In multiple myelomas (MMs), however, these pathway intrinsic mutations are rare despite the fact that most tumors display aberrant Wnt pathway activity. Recent studies indicate that this activation is caused by genetic and epigenetic lesions of Wnt regulatory components, sensitizing MM cells to autocrine Wnt ligands and paracrine Wnts emanating from the bone marrow niche. These include deletion of the tumor suppressor CYLD , promotor methylation of the Wnt antagonists WIF1 , DKK1, DKK3 , and sFRP1 , sFRP2 , sFRP4 , sFRP5 , as well as overexpression of the co-transcriptional activator BCL9 and the R-spondin receptor LGR4. Furthermore, Wnt activity in MM is strongly promoted by interaction of both Wnts and R-spondins with syndecan-1 (CD138) on the MM cell-surface. Functionally, aberrant canonical Wnt signaling plays a dual role in the pathogenesis of MM: (I) it mediates proliferation, migration, and drug resistance of MM cells; (II) MM cells secrete Wnt antagonists that contribute to the development of osteolytic lesions by impairing osteoblast differentiation. As discussed in this review, these insights into the causes and consequences of aberrant Wnt signaling in MM will help to guide the development of targeting strategies. Importantly, since Wnt signaling in MM cells is largely ligand dependent, it can be targeted by drugs/antibodies that act upstream in the pathway, interfering with Wnt secretion, sequestering Wnts, or blocking Wnt (co)receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The aberrant activation of the Wnt/β-catenin pathway is a key feature in the initiation and progression of MM.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the treatment of MM, the bone marrow microenvironment plays a significant role in activating the Wnt/β-catenin pathway through Wnt ligands secreted by bone marrow stromal cells (BMSCs).”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Targeting proteins that mediate these signaling pathways holds promise as a potential therapeutic approach for MM treatment [32, 35–39].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“Aberrant activation of these pathways contributes to the proliferation, survival, migration, and drug resistance of myeloma cells, making them attractive targets for therapeutic intervention.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“The dysregulated Wnt signaling in MM has a dual impact, firstly, it promotes the proliferation, migration, and drug resistance of MM cells; secondly, MM cells secrete Wnt antagonists that inhibit osteoblast differentiation, leading to the progression of osteolytic lesions by impeding bone formation [35, 38, 122].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Functional interaction of β-catenin with the transcription factor LEF-1
Behrens, J., von Kries, J. P., Kühl, M., Bruhn, L., Wedlich, D., Grosschedl, R., & Birchmeier, W. (1996) · Nature · doi:10.1038/382638a0 · Cited by 2,912
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
A role for Wnt signalling in self-renewal of haematopoietic stem cells
Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, L., Nusse, R., & Weissman, I. L. (2003) · Nature · doi:10.1038/nature01593 · Cited by 2,159
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037
XTcf-3 Transcription Factor Mediates β-Catenin-Induced Axis Formation in Xenopus Embryos
Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destrée, O., & Clevers, H. (1996) · Cell · doi:10.1016/s0092-8674(00)80112-9 · Cited by 1,824
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
Cohen, P., & Frame, S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096075 · Cited by 1,478
Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Chen, B., Dodge, M. E., Tang, W., Lu, J., Ma, Z., Fan, C.-W., Wei, S., Hao, W., Kilgore, J., Williams, N. S., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.137 · Cited by 1,383
An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control
Clevers, H., Loh, K. M., & Nusse, R. (2014) · Science · doi:10.1126/science.1248012 · Cited by 1,364
Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling
de Lau, W., Barker, N., Low, T. Y., Koo, B.-K., Li, V. S. W., Teunissen, H., Kujala, P., Haegebarth, A., Peters, P. J., van de Wetering, M., et al. (2011) · Nature · doi:10.1038/nature10337 · Cited by 1,272
The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination
Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israël, A., Wallach, D., & Courtois, G. (2003) · Nature · doi:10.1038/nature01802 · Cited by 1,016
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.003 · Cited by 983
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors
Koo, B.-K., Spit, M., Jordens, I., Low, T. Y., Stange, D. E., van de Wetering, M., van Es, J. H., Mohammed, S., Heck, A. J. R., Maurice, M. M., et al. (2012) · Nature · doi:10.1038/nature11308 · Cited by 980
ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner
Hao, H.-X., Xie, Y., Zhang, Y., Charlat, O., Oster, E., Avello, M., Lei, H., Mickanin, C., Liu, D., Ruffner, H., et al. (2012) · Nature · doi:10.1038/nature11019 · Cited by 972
Recurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB
Brummelkamp, T. R., Nijman, S. M. B., Dirac, A. M. G., & Bernards, R. (2003) · Nature · doi:10.1038/nature01811 · Cited by 952
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
Kühl, M., Sheldahl, L. C., Park, M., Miller, J. R., & Moon, R. T. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02028-x · Cited by 861
Carmon, K. S., Gong, X., Lin, Q., Thomas, A., & Liu, Q. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106083108 · Cited by 855
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Liu, J., Pan, S., Hsieh, M. H., Ng, N., Sun, F., Wang, T., Kasibhatla, S., Schuller, A. G., Li, A. G., Cheng, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314239110 · Cited by 831
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B., & Shaughnessy, J. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 698
Wu, J., Jiao, Y., Dal Molin, M., Maitra, A., de Wilde, R. F., Wood, L. D., Eshleman, J. R., Goggins, M. G., Wolfgang, C. L., Canto, M. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118046108 · Cited by 640
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614
Walker, B. A., Boyle, E. M., Wardell, C. P., Murison, A., Begum, D. B., Dahir, N. M., Proszek, P. Z., Johnson, D. C., Kaiser, M. F., Melchor, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1503 · Cited by 567
Kramps, T., Peter, O., Brunner, E., Nellen, D., Froesch, B., Chatterjee, S., Murone, M., Züllig, S., & Basler, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00679-7 · Cited by 561
The role of RhoA in tissue polarity and Frizzled signalling
Strutt, D. I., Weber, U., & Mlodzik, M. (1997) · Nature · doi:10.1038/387292a0 · Cited by 560
Genomic complexity of multiple myeloma and its clinical implications
Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G., & Ghobrial, I. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 560
DKK1, a negative regulator of Wnt signaling, is a target of the β-catenin/TCF pathway
Niida, A., Hiroko, T., Kasai, M., Furukawa, Y., Nakamura, Y., Suzuki, Y., Sugano, S., & Akiyama, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207892 · Cited by 554
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α
Thorne, C. A., Hanson, A. J., Schneider, J., Tahinci, E., Orton, D., Cselenyi, C. S., Jernigan, K. K., Meyers, K. C., Hang, B. I., Waterson, A. G., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.453 · Cited by 485
Wnt Signaling Regulates B Lymphocyte Proliferation through a LEF-1 Dependent Mechanism
Reya, T., O'Riordan, M., Okamura, R., Devaney, E., Willert, K., Nusse, R., & Grosschedl, R. (2000) · Immunity · doi:10.1016/s1074-7613(00)00004-2 · Cited by 450
Yaccoby, S., Ling, W., Zhan, F., Walker, R., Barlogie, B., & Shaughnessy, J. D. (2007) · Blood · doi:10.1182/blood-2006-09-047712 · Cited by 433
Carrasco, D. R., Tonon, G., Huang, Y., Zhang, Y., Sinha, R., Feng, B., Stewart, J. P., Zhan, F., Khatry, D., Protopopova, M., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.019 · Cited by 425
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma
Jiang, X., Hao, H.-X., Growney, J. D., Woolfenden, S., Bottiglio, C., Ng, N., Lu, B., Hsieh, M. H., Bagdasarian, L., Meyer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307218110 · Cited by 414
Klingensmith, J., Nusse, R., & Perrimon, N. (1994) · Genes & Development · doi:10.1101/gad.8.1.118 · Cited by 405
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., Shen, Z., Patel, N., Tai, Y.-T., Chauhan, D., et al. (2009) · Blood · doi:10.1182/blood-2008-11-191577 · Cited by 399
Albuquerque, C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.13.1549 · Cited by 392
Targeting the bone marrow microenvironment in multiple myeloma
Kawano, Y., Moschetta, M., Manier, S., Glavey, S., Görgün, G. T., Roccaro, A. M., Anderson, K. C., & Ghobrial, I. M. (2015) · Immunological Reviews · doi:10.1111/imr.12233 · Cited by 391
Proffitt, K. D., Madan, B., Ke, Z., Pendharkar, V., Ding, L., Lee, M. A., Hannoush, R. N., & Virshup, D. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2258 · Cited by 382
González-Sancho, J. M., Aguilera, O., García, J. M., Pendás-Franco, N., Peña, C., Cal, S., de Herreros, A. G., Bonilla, F., & Muñoz, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208303 · Cited by 366
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Walker, B. A., Leone, P. E., Chiecchio, L., Dickens, N. J., Jenner, M. W., Boyd, K. D., Johnson, D. C., Gonzalez, D., Dagrada, G. P., Protheroe, R. K. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279596 · Cited by 365
Kadowaki, T., Wilder, E., Klingensmith, J., Zachary, K., & Perrimon, N. (1996) · Genes & Development · doi:10.1101/gad.10.24.3116 · Cited by 348
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
Oshima, T., Abe, M., Asano, J., Hara, T., Kitazoe, K., Sekimoto, E., Tanaka, Y., Shibata, H., Hashimoto, T., Ozaki, S., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4940 · Cited by 345
Wnt addiction of genetically defined cancers reversed by PORCN inhibition
Madan, B., Ke, Z., Harmston, N., Ho, S. Y., Frois, A. O., Alam, J., Jeyaraj, D. A., Pendharkar, V, Ghosh, K., Virshup, I. H., et al. (2016) · Oncogene · doi:10.1038/onc.2015.280 · Cited by 341
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells
Derksen, P. W. B., Tjin, E., Meijer, H. P., Klok, M. D., Mac Gillavry, H. D., van Oers, M. H. J., Lokhorst, H. M., Bloem, A. C., Clevers, H., Nusse, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305855101 · Cited by 307
Self-citationChamorro, M. N., Schwartz, D. R., Vonica, A., Brivanlou, A. H., Cho, K. R., & Varmus, H. E. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600460 · Cited by 298
Derksen, P. W. B., Keehnen, R. M. J., Evers, L. M., van Oers, M. H. J., Spaargaren, M., & Pals, S. T. (2002) · Blood · doi:10.1182/blood.v99.4.1405 · Cited by 274
Self-citationGunn, W. G., Conley, A., Deininger, L., Olson, S. D., Prockop, D. J., & Gregory, C. A. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0220 · Cited by 261
Targeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling
Takada, K., Zhu, D., Bird, G. H., Sukhdeo, K., Zhao, J.-J., Mani, M., Lemieux, M., Carrasco, D. E., Ryan, J., Horst, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003808 · Cited by 245
Heath, D. J., Chantry, A. D., Buckle, C. H., Coulton, L., Shaughnessy, J. D., Evans, H. R., Snowden, J. A., Stover, D. R., Vanderkerken, K., & Croucher, P. I. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081104 · Cited by 243
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis
Davies, F. E., Dring, A. M., Li, C., Rawstron, A. C., Shammas, M. A., O'Connor, S. M., Fenton, J. A. L., Hideshima, T., Chauhan, D., Tai, I. T., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0016 · Cited by 223
Tauriello, D. V. F., Haegebarth, A., Kuper, I., Edelmann, M. J., Henraat, M., Canninga-van Dijk, M. R., Kessler, B. M., Clevers, H., & Maurice, M. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.035 · Cited by 217
Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma
Sukhdeo, K., Mani, M., Zhang, Y., Dutta, J., Yasui, H., Rooney, M. D., Carrasco, D. E., Zheng, M., He, H., Tai, Y.-T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610299104 · Cited by 216
Jimeno, A., Gordon, M., Chugh, R., Messersmith, W., Mendelson, D., Dupont, J., Stagg, R., Kapoun, A. M., Xu, L., Uttamsingh, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2157 · Cited by 209
Luis, T. C., Ichii, M., Brugman, M. H., Kincade, P., & Staal, F. J. T. (2012) · Leukemia · doi:10.1038/leu.2011.387 · Cited by 208
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 207 · cited 2×
“Rosmantuzumab (OMP-131R10) [101] R-spondin 3 Phase I NCT02482441”
Clarke, B. L. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79307-2 · Cited by 200
Mani, M., Carrasco, D. E., Zhang, Y., Takada, K., Gatt, M. E., Dutta-Simmons, J., Ikeda, H., Diaz-Griffero, F., Pena-Cruz, V., Bertagnolli, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0773 · Cited by 185
McDonald, M. M., Reagan, M. R., Youlten, S. E., Mohanty, S. T., Seckinger, A., Terry, R. L., Pettitt, J. A., Simic, M. K., Cheng, T. L., Morse, A., et al. (2017) · Blood · doi:10.1182/blood-2017-03-773341 · Cited by 185
Zhao, J.-J., Lin, J., Zhu, D., Wang, X., Brooks, D., Chen, M., Chu, Z.-B., Takada, K., Ciccarelli, B., Admin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3311-t · Cited by 177
Iyer, S. P., Beck, J. T., Stewart, A. K., Shah, J. J., Kelly, K. R., ISAACS, R. E., Bilic, S., Sen, S., & Munshi, N. C. (2014) · British Journal of Haematology · doi:10.1111/bjh.13056 · Cited by 175
Safely targeting cancer stem cells via selective catenin coactivator antagonism
Lenz, H., & Kahn, M. (2014) · Cancer Science · doi:10.1111/cas.12471 · Cited by 175
Wnt signaling in B-cell neoplasia
Qiang, Y., Endo, Y., Rubin, J. S., & Rudikoff, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206239 · Cited by 163
De Vos, J., Couderc, G., Tarte, K., Jourdan, M., Requirand, G., Delteil, M.-C., Rossi, J.-F., Mechti, N., & Klein, B. (2001) · Blood · doi:10.1182/blood.v98.3.771 · Cited by 161
Christie, M., Jorissen, R. N., Mouradov, D., Sakthianandeswaren, A., Li, S., Day, F., Tsui, C., Lipton, L., Desai, J., Jones, I. T., et al. (2013) · Oncogene · doi:10.1038/onc.2012.486 · Cited by 151
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma
Chim, C. S., Pang, R., Fung, T. K., Choi, C.-L., & Liang, R. H. S. (2007) · Leukemia · doi:10.1038/sj.leu.2404939 · Cited by 147
Syndecan-1: a dynamic regulator of the myeloma microenvironment
Sanderson, R. D., & Yang, Y. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9125-3 · Cited by 143
Fujisawa, K., Fujita, A., Ishizaki, T., Saito, Y., & Narumiya, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23022 · Cited by 143
Driscoll, J. J., Pelluru, D., Lefkimmiatis, K., Fulciniti, M., PRABHALA, R. H., Greipp, P. R., Barlogie, B., Tai, Y., Anderson, K. C., Shaughnessy, J. D., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211045 · Cited by 136
Wnts induce migration and invasion of myeloma plasma cells
Qiang, Y.-W. (2005) · Blood · doi:10.1182/blood-2005-01-0049 · Cited by 134
Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Reagan, M. R., & Ghobrial, I. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2212 · Cited by 132
Bjorklund, C. C., Ma, W., Wang, Z.-Q., Davis, R. E., Kuhn, D. J., Kornblau, S. M., Wang, M., Shah, J. J., & Orlowski, R. Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180208 · Cited by 130
Myeloma cells suppress osteoblasts through sclerostin secretion
Colucci, S., Brunetti, G., Oranger, A., Mori, G., Sardone, F., Specchia, G., Rinaldi, E., Curci, P., Liso, V, Passeri, G., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.22 · Cited by 129
Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression
Dutta-Simmons, J., Zhang, Y., Görgün, G., Gatt, M. E., Mani, M., Hideshima, T., Takada, K., Carlson, N. E., Carrasco, D. E., Tai, Y., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194290 · Cited by 123
Mulligan, G., Lichter, D. I., Di Bacco, A., Blakemore, S. J., Berger, A., Koenig, E., Bernard, H., Trepicchio, W., Li, B., Neuwirth, R., et al. (2014) · Blood · doi:10.1182/blood-2013-05-504340 · Cited by 118
Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma
Selvanayagam, P., Blick, M. B., Narni, F., van Tuinen, P., Ledbetter, D., Alexanian, R., Saunders, G., & Barlogie, B. (1988) · Blood · doi:10.1182/blood.v71.1.30.30 · Cited by 105
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Qiang, Y.-W., Shaughnessy, J. D., & Yaccoby, S. (2008) · Blood · doi:10.1182/blood-2007-10-120253 · Cited by 95
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications
Gonzalez-Paz, N., Chng, W. J., McClure, R. F., Blood, E., Oken, M. M., Ness, B. V., James, C. D., Kurtin, P. J., Henderson, K., Ahmann, G. J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-024661 · Cited by 94
Kobune, M., Chiba, H., Kato, J., Kato, K., Nakamura, K., Kawano, Y., Takada, K., Takimoto, R., Takayama, T., Hamada, H., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0684 · Cited by 92
Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins
Ren, Z., van Andel, H., de Lau, W., Hartholt, R. B., Maurice, M. M., Clevers, H., Kersten, M. J., Spaargaren, M., & Pals, S. T. (2018) · Blood · doi:10.1182/blood-2017-07-797050 · Cited by 87
Self-citationMUC1-C drives MYC in multiple myeloma
Tagde, A., Rajabi, H. N., Bouillez, A., Alam, M., Gali, R. R., Bailey, S. T., Tai, Y., Hideshima, T., Anderson, K. C., Avigan, D., et al. (2016) · Blood · doi:10.1182/blood-2015-07-659151 · Cited by 84
Bolli, N., Li, Y., Sathiaseelan, V, Raine, K., Jones, D., Ganly, P., Cocito, F., Bignell, G., Chapman, M. A., Sperling, A. S., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.72 · Cited by 80
Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma
Reijmers, R. M., Groen, R. W. J., Rozemuller, H., Kuil, A., de Haan-Kramer, A., Csikós, T., Martens, A. C. M., Spaargaren, M., & Pals, S. T. (2010) · Blood · doi:10.1182/blood-2009-02-204396 · Cited by 79
Self-citationOsteoblastic niche supports the growth of quiescent multiple myeloma cells
Chen, Z., Orlowski, R. Z., Wang, M., Kwak, L., & McCarty, N. (2014) · Blood · doi:10.1182/blood-2013-07-517136 · Cited by 77
Ashihara, E., Kawata, E., Nakagawa, Y., Shimazaski, C., Kuroda, J., Taniguchi, K., Uchiyama, H., Tanaka, R., Yokota, A., Takeuchi, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1350 · Cited by 66
Kocemba‐Pilarczyk, K. A., Groen, R. W. J., van Andel, H., Kersten, M. J., Mahtouk, K., Spaargaren, M., & Pals, S. T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030359 · Cited by 58
Self-citationvan Andel, H., Kocemba‐Pilarczyk, K. A., de Haan-Kramer, A., Mellink, C. H. M., Piwowar, M. W., Broijl, A., van Duin, M., Sonneveld, P., Maurice, M. M., Kersten, M. J., et al. (2016) · Oncogene · doi:10.1038/onc.2016.368 · Cited by 56
Self-citationReijmers, R. M., Spaargaren, M., & Pals, S. T. (2013) · The FEBS Journal · doi:10.1111/febs.12180 · Cited by 55
Self-citationvan Andel, H., Ren, Z., Koopmans, I., Joosten, S. P. J., Kocemba, K. A., de Lau, W., Kersten, M. J., de Bruin, A. M., Guikema, J. E. J., Clevers, H., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618650114 · Cited by 51
Self-citationSavvidou, I., Khong, T., Cuddihy, A., McLean, C., Horrigan, S., & Spencer, A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0624 · Cited by 50
β-catenin SUMOylation is involved in the dysregulated proliferation of myeloma cells.
Huang, H., Zhou, L., Fu, W., Zhang, C.-Y., Jiang, H., Du, J., & Hou, J. Q. (2015) · Europe PMC (PubMed Central) · Cited by 48
Yao, H., Ashihara, E., Strovel, J. W., Nakagawa, Y., Kuroda, J., Nagao, R., Tanaka, R., Yokota, A., Takeuchi, M., Hayashi, Y., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.41 · Cited by 48 · cited 2×
“LGK974 [30, 102] Porcupine (Wnt secretion) Phase I NCT01351103, NCT02278133 ETC-159 [103] Porcupine (Wnt secretion) Phase I NCT02521844 C59 [104] Porcupine (Wnt secretion) Preclinical IWP-2 [105] Porcupine (Wnt secretion) Preclinical XAV939 [106] Tankyrase (Axin stabilization) Preclinical IWR [105] Tankyrase (Axin sta…”
ResultMyeloma bone disease: pathogenesis and treatment.
Roodman, G. D. (2005) · PubMed · Cited by 46
Kristensen, I. B., Christensen, J. H., Lyng, M., Møller, M. B., Pedersen, L., Rasmussen, L. M., Ditzel, H. J., & Abildgaard, N. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.820288 · Cited by 40
Gunn, W., Krause, U., Lee, N., & Gregory, C. A. (2010) · Blood · doi:10.1182/blood-2010-09-308171 · Cited by 39
Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma
Jost, E., Gezer, D., Wilop, S., Suzuki, H., Herman, J. G., Osieka, R., & Galm, O. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.002 · Cited by 37
GP130 activation induces myeloma and collaborates with MYC
Dechow, T., Steidle, S., Götze, K. S., Rudelius, M., Behnke, K., Pechloff, K., Kratzat, S., Bullinger, L., Fend, F., Soberon, V., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69094 · Cited by 36
Myeloma bone disease: pathogenesis and treatment.
O'Donnell, E. K., & Raje, N. S. (2017) · PubMed · Cited by 36
B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma
Fulciniti, M., Vallet, S., Ettenberg, S. A., Shen, X., Raje, N. S., Tassone, P., Hideshima, T., Nanjappa, P., PRABHALA, R. H., Anderson, K. C., et al. (2009) · Clinical Lymphoma & Myeloma · doi:10.1016/s1557-9190(11)70775-2 · Cited by 28
Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells
Xu, F., Zhu, Y., Lu, Y., Yu, Z., Zhong, J., Li, Y., & Pan, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8006 · Cited by 26 · cited 2×
“Pyrvinium [40] CK1α activation Preclinical”
ResultTao, H., Shinmura, K., Yamada, H., Maekawa, M., Osawa, S., Takayanagi, Y., Okamoto, K., Terai, T., Mori, H., Nakamura, T., et al. (2010) · BMC Research Notes · doi:10.1186/1756-0500-3-305 · Cited by 17
Choi, P. J., Yuseok, O., Her, J.-H., Yun, E., Song, G., & Oh, S. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.07.001 · Cited by 16
Cited by
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“The physiological mechanism associated with DKK1 involves the activation of DKK1 transcription through the Wnt/β-catenin signaling pathway, which then binds to LRP5/6 and blocks the recognition of Wnt ligands, thereby forming a negative feedback loop that inhibits Wnt signaling [352].”
BackgroundWnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease
Hu, L., Chen, W., Qian, A., & Li, Y.-P. (2024) · Bone Research · doi:10.1038/s41413-024-00342-8 · Cited by 359
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Martin-Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I., & Ayala-San Nicolas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 286
Metadata
- Authors
- van Andel, H., Kocemba, K. A., Spaargaren, M., & Pals, S. T.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Pals, Steven T.
- Venue
- Leukemia
- Published
- 2019-02-15
- Volume
- 33
- Issue
- 5
- Pages
- 1063-1075
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC6756057
- OpenAlex
- W2913434193
- Semantic Scholar
- dae5444f35c2d5a06a453e98f9836163ac7a4a81
- Cited by
- 188
- References
- 117
- Citations by year
- 2026: 19 · 2025: 22 · 2024: 21 · 2023: 23 · 2022: 32 · 2021: 41 · 2020: 23 · 2019: 7
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Leukemia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- KWF Kankerbestrijding
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Keywords
- multiple myeloma, Wnt/β-catenin signaling, Wnt antagonists, WIF1, DKK1, DKK3, secreted frizzled-related proteins, BCL9, LGR4, R-spondin, bone marrow microenvironment, osteolytic lesions, drug resistance, Wnt inhibitors, Wnt secretion
- MeSH terms
- Animals, Antineoplastic Agents, Bone Diseases, Humans, Ligands, Multiple Myeloma, Protein Binding, Protein Processing, Post-Translational, Biomarkers, Gene Expression Regulation, Neoplastic, Gene Deletion, Autocrine Communication, Paracrine Communication, Gene Silencing, Epigenesis, Genetic, Molecular Targeted Therapy, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.